Pituitary ACTH Hypersecretion clinical trials
The registry lists 64 studies for Pituitary ACTH Hypersecretion across more than 10 countries. 16 are recruiting or about to start. 42 of them are mainly about Pituitary ACTH Hypersecretion (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.
Get an email when these change. Save the Pituitary ACTH Hypersecretion studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Novartis Pharmaceuticals (8) · Corcept Therapeutics (8) · National Institute of Neurological Disorders and Stroke (NINDS) (3) · Mayo Clinic (3) · RECORDATI GROUP (2) · Huashan Hospital (2) · Hospices Civils de Lyon (2) · University of Roma La Sapienza (2)
What is being tested here
Drugs under test in Pituitary ACTH Hypersecretion studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 5
- Nov 2026Collecting Information About Treatment Results for Patients With Cushing's Syndrome · Memorial Sloan Kettering Cancer Center
- Dec 2026Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome · Corcept Therapeutics
- Jan 2027Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors · Mayo Clinic
- Aug 2027A Trial of Lu AG13909 in Adult Participants With Cushing's Disease · H. Lundbeck A/S
- Nov 2027Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors. · Hospices Civils de Lyon
Who these studies take
Of the 12 Pituitary ACTH Hypersecretion studies recruiting now, 7 (58%) set no upper age limit and 2 (17%) stop at 75 or younger. 6 (50%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 5 (42%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 5 (42%) | 5 (42%) |
| 18 | 12 (100%) | 12 (100%) |
| 30 | 12 (100%) | 12 (100%) |
| 40 | 12 (100%) | 12 (100%) |
| 50 | 12 (100%) | 12 (100%) |
| 65 | 12 (100%) | 12 (100%) |
| 75 | 11 (92%) | 11 (92%) |
| 85 | 9 (75%) | 9 (75%) |
Across all 64 studies, recruiting or not: 27% stop at 75 or younger and 13% at 65; 17% take children; 2% are for women only and 2% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Started recruiting1
- Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid DisordersOct 20, 2026NCT04374721
Studies
Recruiting first, then most recently updated. Showing 50 of 64. Browse all 64 → or search them.
- Adrenal Diseases in the Population of Modena: A Clinical-Epidemiological Database of Patients Referred to the Adrenal Disorders Outpatient Clinic of the Clinical Unit of Endocrinology at the Modena University Hospital (AOU Modena)RecruitingNCT079201981 country
- Long-Term Follow-Up of Survivors of Pediatric Cushing DiseaseRecruitingNCT038319581 country
- FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing DiseaseRecruitingNCT07460232Early Phase 11 country
- Collecting Information About Treatment Results for Patients With Cushing's SyndromeRecruitingNCT033648031 country
- Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid DisordersRecruitingNCT04374721Not applicable1 country
- An Investigation of Pituitary Tumors and Related Hypothalmic DisordersRecruitingNCT000015951 country
- PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary TumoursNot yet recruitingNCT07813351Phase 3
- Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)RecruitingNCT045432531 country
- Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing DiseaseRecruitingNCT05971758Phase 21 country
- Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's DiseaseEnrolling by invitationNCT07108244Not applicable2 countries
- Combination Osilodrostat and Cabergoline in Cushing's DiseaseEnrolling by invitationNCT07603466Phase 41 country
- DDAVP for Pituitary AdenomaRecruitingNCT04569591Not applicable1 country
- Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors.RecruitingNCT074636251 country
- Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary TumorsRecruitingNCT073353151 country
- Modified Desmopressin (mDesmo) Using Cold-Kit for PET/CTRecruitingNCT069622021 country
- Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma DetectionNot yet recruitingNCT06701838
- Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromeActive, not recruitingNCT03604198Phase 210 countries
- A Trial of Lu AG13909 in Adult Participants With Cushing's DiseaseActive, not recruitingNCT06471829Phase 29 countries
- Multicenter Study of Seliciclib (R-roscovitine) for Cushing DiseaseCompletedNCT03774446Phase 21 country
- A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's SyndromeCompletedNCT05804669Phase 1/21 country
- Health Status of the Patients Followed for a Disease of Cushing in the Region Large-West of 1990 to 2015WithdrawnNCT03297892
- Cushing's Disease ComplicationsCompletedNCT025689821 country
- Assessment of Persistent Cognitive Impairment After Cure of Cushing's DiseaseCompletedNCT02603653Not applicable1 country
- Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of HypercorticismsActive, not recruitingNCT039747891 country
- SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's SyndromeCompletedNCT05307328Phase 23 countries
- Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's DiseaseCompletedNCT03346954Not applicable1 country
- A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing SyndromeCompletedNCT03697109Phase 311 countries
- Postoperative Thrombosis Prevention in Patients With CDActive, not recruitingNCT04486859Not applicable1 country
- Open-label Treatment in Cushing's SyndromeCompletedNCT03621280Phase 311 countries
- Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s DiseaseWithdrawnNCT04339751Phase 21 country
- Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's DiseaseCompletedNCT0231026911 countries
- Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored StudiesCompletedNCT01794793Phase 428 countries
- Diagnostic Yield of Deep Learning Based Denoising MRI in Cushing's DiseaseTerminatedNCT041219881 country
- Hair Cortisol and Cushing's DiseaseCompletedNCT04201444Not applicable1 country
- The Circadian Rhythm in CusHing SyndrOme in Active Phase and dUring RemiSsion (TheHOURS)Status unknownNCT033434701 country
- Vitamin D Metabolism in Patients With Endocrine DisordersCompletedNCT04844164Phase 11 country
- Efficacy and Safety Evaluation of Osilodrostat in Cushing's DiseaseCompletedNCT02697734Phase 314 countries
- Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's DiseaseCompletedNCT00171951Phase 25 countries
- Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 InhibitionCompletedNCT03111810Phase 21 country
- Treatment for Endogenous Cushing's SyndromeCompletedNCT01838551Phase 315 countries
- Safety and Efficacy of LCI699 in Cushing's Disease PatientsCompletedNCT01331239Phase 24 countries
- Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's DiseaseTerminatedNCT01915303Phase 216 countries
- Long-term Cardiovascular Risk in Cured Cushing's PatientsTerminatedNCT008812831 country
- Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)TerminatedNCT00612066Phase 21 country
- Nailfold Capillaroscopy Evaluation in Cushing Syndrome PatientsStatus unknownNCT044338191 country
- Seoul National University Pituitary Disease Cohort StudyStatus unknownNCT034746011 country
- Study to Evaluate CORT125134 in Participants With Cushing's SyndromeCompletedNCT02804750Phase 25 countries
- Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or AcromegalyCompletedNCT02060383Phase 412 countries
- Cushing´s Disease Epidemiology in SwedenCompletedNCT023501531 country
- Prevention of Metabolic Complications of Glucocorticoid ExcessCompletedNCT01319994Phase 2/31 country